# Supplemental Digital Content 4. Non-inferiority of the geometric mean concentrations of antibodies against pertussis antigens 28 days after Tdap administration in the concomitant and sequential groups in baseline dengue seropositive participants - FAS

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Concomitant (N=338)** | | | **Sequential (N=342)** | | | **Concomitant / Sequential** | | |
| **Component** | **M** | **GMC** | **95% CI** | **M** | **GMC** | **95% CI** | **GMC ratio** | **95% CI** | **Overall non-inferiority** |
| **Anti-PT (ELISA - EU/mL)** | 301 | 65 | 57.5 73.5 | 311 | 76.1 | 68.1, 85.2 | 0.845 | 0.719, 0.992 | Yes |
| **Anti-FHA (ELISA - EU/mL)** | 309 | 272 | 248, 299 | 315 | 266 | 240, 295 | 1.02 | 0.893, 1.18 |
| **Anti-PRN (ELISA - EU/mL)** | 312 | 50.6 | 41.4, 61.8 | 315 | 45.0 | 36.8, 55.1 | 1.11 | 0.838, 1.46 |
| **Anti-FIM (ELISA - EU/mL)** | 310 | 700 | 583, 841 | 313 | 642 | 537, 769 | 1.04 | 0.825, 1.32 |

CI, confidence interval; FAS, full analysis set; GMC, geometric mean concentration; FIM, fimbriae types 2 and 3; FHA filamentous hemagglutinin; M, number of participants with available data for the relevant endpoint; N, sample number; PRN, pertactin; PT, pertussis toxoid

The non-inferiority was met if the lower limit of the two-sided 95% CI of the GMC ratio (concomitant / sequential) was >0.667 for eachantigen. Overall non-inferiority was met if the four antigens achieved non-inferiority.